CL2014002500A1 - Vaccine against respiratory syncytial virus (vsr) comprising a recombinant human adenovirus serotype 35 comprising nucleic acid encoding a protein vsr f; a method to vaccinate a subject against vsr; cell comprising a recombinant human adenovirus serotype 35; method to make a vaccine against vsr; Recombinant nucleic acid encoding protein vsr. - Google Patents
Vaccine against respiratory syncytial virus (vsr) comprising a recombinant human adenovirus serotype 35 comprising nucleic acid encoding a protein vsr f; a method to vaccinate a subject against vsr; cell comprising a recombinant human adenovirus serotype 35; method to make a vaccine against vsr; Recombinant nucleic acid encoding protein vsr.Info
- Publication number
- CL2014002500A1 CL2014002500A1 CL2014002500A CL2014002500A CL2014002500A1 CL 2014002500 A1 CL2014002500 A1 CL 2014002500A1 CL 2014002500 A CL2014002500 A CL 2014002500A CL 2014002500 A CL2014002500 A CL 2014002500A CL 2014002500 A1 CL2014002500 A1 CL 2014002500A1
- Authority
- CL
- Chile
- Prior art keywords
- vsr
- nucleic acid
- acid encoding
- protein
- human adenovirus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614429P | 2012-03-22 | 2012-03-22 | |
| EP12160682 | 2012-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014002500A1 true CL2014002500A1 (en) | 2015-01-16 |
Family
ID=52580709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002499A CL2014002499A1 (en) | 2012-03-22 | 2014-09-22 | Vaccine against respiratory syncytial virus (vsr) comprising a recombinant human adenovirus serotype 26 comprising nucleic acid encoding protein vsr fragment or fragment thereof; method to vaccinate against vsr; cell comprising recombinant human adenovirus serotype 26; method to manufacture the vaccine; Recombinant nucleic acid encoding protein vsr. |
| CL2014002500A CL2014002500A1 (en) | 2012-03-22 | 2014-09-22 | Vaccine against respiratory syncytial virus (vsr) comprising a recombinant human adenovirus serotype 35 comprising nucleic acid encoding a protein vsr f; a method to vaccinate a subject against vsr; cell comprising a recombinant human adenovirus serotype 35; method to make a vaccine against vsr; Recombinant nucleic acid encoding protein vsr. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002499A CL2014002499A1 (en) | 2012-03-22 | 2014-09-22 | Vaccine against respiratory syncytial virus (vsr) comprising a recombinant human adenovirus serotype 26 comprising nucleic acid encoding protein vsr fragment or fragment thereof; method to vaccinate against vsr; cell comprising recombinant human adenovirus serotype 26; method to manufacture the vaccine; Recombinant nucleic acid encoding protein vsr. |
Country Status (8)
| Country | Link |
|---|---|
| KR (1) | KR20190107182A (en) |
| BR (1) | BR112014023195B1 (en) |
| CL (2) | CL2014002499A1 (en) |
| HK (2) | HK1206272A1 (en) |
| IL (2) | IL234758A (en) |
| MX (2) | MX352908B (en) |
| PH (2) | PH12014502013A1 (en) |
| ZA (2) | ZA201406890B (en) |
-
2013
- 2013-03-21 KR KR1020197026325A patent/KR20190107182A/en not_active Application Discontinuation
- 2013-03-21 MX MX2014011341A patent/MX352908B/en active IP Right Grant
- 2013-03-21 MX MX2014011340A patent/MX351482B/en active IP Right Grant
- 2013-03-21 BR BR112014023195-8A patent/BR112014023195B1/en active IP Right Grant
-
2014
- 2014-09-09 PH PH12014502013A patent/PH12014502013A1/en unknown
- 2014-09-19 ZA ZA2014/06890A patent/ZA201406890B/en unknown
- 2014-09-19 ZA ZA2014/06892A patent/ZA201406892B/en unknown
- 2014-09-21 IL IL234758A patent/IL234758A/en active IP Right Grant
- 2014-09-21 IL IL234760A patent/IL234760A/en active IP Right Grant
- 2014-09-22 CL CL2014002499A patent/CL2014002499A1/en unknown
- 2014-09-22 PH PH12014502086A patent/PH12014502086A1/en unknown
- 2014-09-22 CL CL2014002500A patent/CL2014002500A1/en unknown
-
2015
- 2015-07-22 HK HK15106981.1A patent/HK1206272A1/en unknown
- 2015-07-22 HK HK15106989.3A patent/HK1206274A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12014502086B1 (en) | 2014-11-24 |
| PH12014502013B1 (en) | 2014-11-24 |
| CL2014002499A1 (en) | 2015-01-09 |
| BR112014023195B1 (en) | 2021-05-04 |
| ZA201406892B (en) | 2015-12-23 |
| MX2014011341A (en) | 2015-05-11 |
| ZA201406890B (en) | 2015-12-23 |
| KR20190107182A (en) | 2019-09-18 |
| MX351482B (en) | 2017-10-03 |
| IL234760A (en) | 2016-07-31 |
| MX352908B (en) | 2017-12-13 |
| HK1206274A1 (en) | 2016-01-08 |
| IL234758A (en) | 2016-07-31 |
| MX2014011340A (en) | 2015-05-11 |
| PH12014502013A1 (en) | 2014-11-24 |
| PH12014502086A1 (en) | 2014-11-24 |
| HK1206272A1 (en) | 2016-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ630649A (en) | Vaccine against rsv | |
| BR112018008102A2 (en) | respiratory syncytial virus vaccine | |
| MD3718565T2 (en) | Respiratory virus vaccines | |
| BR112014012681A8 (en) | polypeptide, designed to provide a polypeptide, nucleic acid, and immunogenic composition | |
| BR112015002981A2 (en) | stable vaccine, and methods for vaccinating a canine, and for making the stable vaccine | |
| SG11201510746WA (en) | Respiratory syncytial virus (rsv) vaccine | |
| BR112013020070A2 (en) | nucleic acid molecules encoding new herpes antigens, vaccine comprising them and methods of using them | |
| BR112015013095A2 (en) | cannula to minimize dosage dilution during nitric oxide distribution. | |
| SI2879702T1 (en) | Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine | |
| MD20120127A2 (en) | Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV | |
| EP2836505A4 (en) | Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same | |
| HK1214520A1 (en) | Treatment of diabetes mellitus by long acting formulations of insulins | |
| SG10201707607PA (en) | Polysialic acid, blood group antigens and glycoprotein expression | |
| CL2015000642A1 (en) | Nucleic acid molecule encoding a salmonoid alphavirus polypeptide (sav) or salmon pancreas disease virus (spdv); encoded polypeptide; method to induce immune response against salmon alphavirus; and vaccine. | |
| EP2968519A4 (en) | Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom | |
| CL2014003185A1 (en) | Low viscosity preformulation comprising pasireotide, somatostatin receptor agonist; preformulation preparation process; pharmaceutical kit; Use to treat cushing disease or acromegaly. | |
| EA201592298A1 (en) | HUMAN VIRAL VACCINE AGAINST THE RESPIRATORY SYNCTIAL VIRUS | |
| CL2015001618A1 (en) | Vaccination adjuvant, preparation and vaccines containing it | |
| BR112015017492A2 (en) | insulin analog, nucleic acid, expression vector, host cell, method for lowering a patient's blood sugar, method for preparing b1-b3 residue-deficient insulin analogs and polypeptide | |
| CL2014000760A1 (en) | Isolated and purified antimicrobial peptide of tilapia gills (oreochromis niloticus); nucleic acid encoding it; composition that includes it; and its use for the control of pathogens and as a molecular adjuvant in a vaccine composition to increase the immune response against the vaccine antigen. | |
| CL2014002500A1 (en) | Vaccine against respiratory syncytial virus (vsr) comprising a recombinant human adenovirus serotype 35 comprising nucleic acid encoding a protein vsr f; a method to vaccinate a subject against vsr; cell comprising a recombinant human adenovirus serotype 35; method to make a vaccine against vsr; Recombinant nucleic acid encoding protein vsr. | |
| EA201592299A1 (en) | HUMAN VIRAL VACCINE AGAINST THE RESPIRATORY SYNCTIAL VIRUS | |
| ITTO20130872A1 (en) | PROCEDURE FOR ADMINISTRATING AN ECTOPARASSITIS AGENT TO A DOG. | |
| DK2768527T3 (en) | MULTI-CBV VACCINE FOR PREVENTING OR TREATING TYPE 1 DIABETES | |
| Montero | Response to Robert J. Howell’s commentary |